The global alpha emitter market size was estimated to be USD 0.681 billion in 2023 and is expected to reach USD 2.26 billion by 2034 with a CAGR of 11.51% during the forecast period 2024-2034. Market growth will be driven by factors such as expanding industrial applications, increased awareness and research, fast technological improvements, regulatory approvals and market expansion, and the rising prevalence of cancer and targeted alpha treatment.
The focused character of alpha particles makes them appealing for cancer treatment because they offer highly localized radiation with little harm to neighboring tissues. This is especially important for malignancies that are aggressive and challenging to treat. For instance, in June 2023, Bayer AG acquired BlueSphere Therapeutics, acquiring access to Lu-PSMA-617, a promising alpha treatment for prostate cancer.
By type of radionuclide, the radium-223 (Ra-223) segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the increased adoption of Ra-223 in cancer treatment, particularly for metastatic bone cancer. The effectiveness of Ra-223 in targeting cancer cells, coupled with ongoing clinical trials showcasing its therapeutic benefits, contributed to a surge in demand. For instance, in September 2023, Novartis International AG partnered with Alpha Tau Medical to create a targeted alpha treatment for prostate cancer that is resistant to castration. Additionally, the astatine-211 (At-211) segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising interest in targeted alpha-particle cancer therapies and ongoing research initiatives exploring the unique properties of Astatine-211.
By medical application, the prostate cancer segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the growing prevalence of prostate cancer worldwide and the successful clinical outcomes observed with alpha emitter-based therapies, particularly in the treatment of advanced-stage prostate cancer. For instance, in December 2022, Mallinckrodt Pharmaceuticals sold its nuclear medicine division to Curium Pharma, which included Actharide (ACTH), which is used to treat bone metastases. Additionally, the bone metastasis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cancers that commonly metastasize to the bones, such as breast and prostate cancer.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the increased adoption of alpha emitter-based therapies for cancer treatment and diagnostic applications, with hospitals serving as key hubs for patient care and medical procedures. For instance, in October 2023, Eckert & Ziegler partnered with Bayer to develop and market Radium-223 generators for the treatment of prostate cancer. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards specialized and focused healthcare services, coupled with an increasing emphasis on personalized and targeted therapies in the medical field.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of cancer cases, and extensive research and development activities in the field of alpha emitter applications. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of alpha emitter applications, rising healthcare investments, and a growing patient pool in the region. For instance, in August 2023, Curium Pharma partnered with GE Healthcare to gain access to the VECTRATM platform for the manufacturing of alpha and beta radiopharmaceuticals.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The focused character of alpha particles makes them appealing for cancer treatment because they offer highly localized radiation with little harm to neighboring tissues. This is especially important for malignancies that are aggressive and challenging to treat. For instance, in June 2023, Bayer AG acquired BlueSphere Therapeutics, acquiring access to Lu-PSMA-617, a promising alpha treatment for prostate cancer.
By type of radionuclide, the radium-223 (Ra-223) segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the increased adoption of Ra-223 in cancer treatment, particularly for metastatic bone cancer. The effectiveness of Ra-223 in targeting cancer cells, coupled with ongoing clinical trials showcasing its therapeutic benefits, contributed to a surge in demand. For instance, in September 2023, Novartis International AG partnered with Alpha Tau Medical to create a targeted alpha treatment for prostate cancer that is resistant to castration. Additionally, the astatine-211 (At-211) segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising interest in targeted alpha-particle cancer therapies and ongoing research initiatives exploring the unique properties of Astatine-211.
By medical application, the prostate cancer segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the growing prevalence of prostate cancer worldwide and the successful clinical outcomes observed with alpha emitter-based therapies, particularly in the treatment of advanced-stage prostate cancer. For instance, in December 2022, Mallinckrodt Pharmaceuticals sold its nuclear medicine division to Curium Pharma, which included Actharide (ACTH), which is used to treat bone metastases. Additionally, the bone metastasis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cancers that commonly metastasize to the bones, such as breast and prostate cancer.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global alpha emitter market in 2023 owing to the increased adoption of alpha emitter-based therapies for cancer treatment and diagnostic applications, with hospitals serving as key hubs for patient care and medical procedures. For instance, in October 2023, Eckert & Ziegler partnered with Bayer to develop and market Radium-223 generators for the treatment of prostate cancer. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards specialized and focused healthcare services, coupled with an increasing emphasis on personalized and targeted therapies in the medical field.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of cancer cases, and extensive research and development activities in the field of alpha emitter applications. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of alpha emitter applications, rising healthcare investments, and a growing patient pool in the region. For instance, in August 2023, Curium Pharma partnered with GE Healthcare to gain access to the VECTRATM platform for the manufacturing of alpha and beta radiopharmaceuticals.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type of Radionuclide, Medical Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Alpha Emitter Market Report 2023 - 2034
Alpha Emitter Market Analysis & Forecast by Type of Radionuclide 2023 - 2034 (Revenue USD Bn)
- Astatine [At-211]
- Radium [Ra-223]
- Lead [Pb-212]
- Bismuth [Bi-212]
- Actinium [Ac-225]
- Others
Alpha Emitter Market Analysis & Forecast by Medical Application 2023 - 2034 (Revenue USD Bn)
- Prostate Cancer
- Bone Metastasis
- Ovarian Cancer
- Pancreatic Cancer
- Endocrine Tumors
- Others
Alpha Emitter Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Alpha Emitter Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Alpha Emitter Market: Type of Radionuclide Estimates & Trend Analysis
8. Alpha Emitter Market: Medical Application Estimates & Trend Analysis
9. Alpha Emitter Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Alpha Emitter Market
12. Europe Global Alpha Emitter Market
13. Asia Pacific Global Alpha Emitter Market
14. Latin America Global Alpha Emitter Market
15. MEA Global Alpha Emitter Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Bayer AG
- Novartis International AG
- GE Healthcare
- Mallinckrodt Pharmaceuticals
- Eckert & Ziegler
- Curium Pharma
- Orano Med
- JSC Isotope
- Alpha Tau Medical
- Nordion (a subsidiary of Sterigenics)
- Algeta (acquired by Bayer)
- Shield TherapeuticsClarity Pharmaceuticals
- ITM Isotopen Technologien München AG
- Endocyte
- (acquired by Novartis)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.68 Billion |
| Forecasted Market Value ( USD | $ 2.26 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
